- Singapore’s biotech sector thrives despite criticism.
- Startups secure million-dollar deals from global pharma companies.
- Industry leaders remain optimistic about long-term growth potential.
Petri dish dreams, billion-dollar schemes
Singapore’s biotech sector is quietly making waves, despite flying under the radar. Critics may point to a lack of standout successes, but industry insiders argue that traditional tech startup metrics don’t apply here.
The sector has seen significant triumphs, including local firms securing millions in licensing deals from global pharmaceutical companies.
Lab coats and growing pains: the Biotech blues
Biotech startups face a unique journey, often spending 8-10 years in drug development before seeing revenue.
Singapore’s ecosystem, barely a decade old, is already showing promise. Mirxes CEO Lihan Zhou points out that compared to mature biotech hubs like Boston or San Francisco, which took 4-5 decades to develop, Singapore’s progress is impressive.
The sector faces challenges, including a shortage of late-stage investors and experienced talent. However, initiatives are underway to address these issues.
Companies like ClavystBio are working to attract industry veterans and expand investor networks.
Despite setbacks like high-profile shutdowns, industry leaders remain optimistic, viewing such events as part of the natural cycle of innovation and growth in biotech.
To read the original article: https://www.techinasia.com/singapores-biotech-sector-successful-people
